

REFERENCES

- Albers, J.A.; Adolphson, J.L. and Hazzard, W.R. (1977):*
Radioimmunoassay of human plasma Lp (a)
Journal of lipid Reserch, 18:331.
- Albers, J.J.; Cabana, V.G.; Warnick, G.R. and Hazzard, W.R. (1975):*
Lp (a): Relationship to sinking pre-B lipoprotein,
hyperlipoproteinaemia, and apolipoprotein B.
Matabolism, 24: 1047.
- Albers, J.J.; Chen, C.H. and Aladjem, F. (1972):*
Human serum lipoproteins. Evidence for three classes of
lipoproteins S_f 0-2.
Biochemistry, 11:57.
- Albers, J.J.; Marcovina, S.M. and Lodge, M.S. (1990):*
The unique Lp (a): properties and immunochemical
measurment.
Clin. Chem, 36: 2019.
- Allan, S.; Babie, T.; Jaques, G.; Sholom, W. and Peter, K. (1985):*
Familial aggregation and early experssion of hyper
betalipoproteinaemia.
Am. J. Cardiol. 55: 291-295.
- Armstrong, V.W.; Cremer, P.; Eberle, E.; Monke, A.; Schulze, F.; Wiel
and H. Kreuzer, H. and Seidel, D. (1986):*
The association between serum Lp (a) concentration and
angiographically assessed coronary atherosclerosis.
Dependence on serum LDL levels. Atherosclerosis, 62:249.
- Backer, G.; Hulstaert, F.; Van, P. and Dramaix, M. (1986):*
Serum lipids and lipoproteins in students whose parents
suffered prematurely from a MI.
Am. Heart. J. 112:478.
- Bainton, D.; Miller, N.E.; Batton, C.H.; Sweetnam, P.M.; Baker, I.A.;
Lewis B. and Elwood, P.C. (1992):*
Plasma TG and HDL-C as predictors of IHD in British men
Br. Heart. J., 68: 60-66.

Barbir, M.; Wile, D. and Trayner, I. (1988):

High prevalence of hypertriglyceridaemia and apolipoprotein abnormalities in CAD.

Br. Heart. J., 60:397-403.

Beisiegel, U.; Utermann, G. and Weber, W. (1986):

Clinical and metabolic aspects of the Lp (a) antigen. In: Atherosclerosis, 1st edition, Vol, VII-Fidge, N.H. and Nestel, P.J. Excerpta Medica, International congress series 696. Elsevier Science publishers BV, Amsterdam, Netherlands, P. 291.

Berg, K. (1963):

A new serum type system in man: the Lp system.

Acta pathol. Microbiol. Scand., 59:369.

Berg, K. (1968):

The Lp system.

Ser. Haematol., 1:111.

Berg, K. (1979):

In herited lipoprotein variations and atherosclerotic diseases.

In: The biochemistry of atherosclerosis, 2nd edition:

Wissler, R. and Getz, G. (eds)

New York, Marcel Dekker Inc., P. 419.

Berg, K.; Hames, C.; Dahlen, G.; Frick, M.H. and Krishan, I. (1976):

Genetic lipoprotein variation and lipid levels in man.

Clinical Genetics, 10:97.

Boerwinkle, E.; Menzel, H.J.; Kraft, H.G. and Utermann, G. (1989):

Genetics of the quantitation Lp (a) trait III contribution of Lp (a) glycoprotein phenotypes to normal lipid variation.

Human Genetics., 82: 73.

Braunwald, E.; Petersdorf, R.; Willson, J.D. (1980):

Genetic predisposition of IHD. Harrison principles of internal medicine 9th ed. page 156.

- Brewer, H.B.; Gregg, R.E.; Hoeg, J.M. and Fojo, S.S. (1988):**
Apolipoproteins and lipoproteins in human plasma. An overview.
Clin. Chem., 34: 84.
- Brown, M.S. and Goldstein, J.L. (1987):**
Teaching old dogmas new tricks.
Nature, 330:113.
- Buja, L.M. and Willerson, J.T. (1987):**
The role of coronary artery lesions in IHD, in: sights from recent clinico-pathologic, coronary arteriographic and experimental studies.
Hum. Path. 18:451.
- Bush, T.L. and Riedle, D. (1991):**
Screening for total cholesterol. Do the national cholesterol education program's recommendations defect individuals at high risk of CAD?
Circulation, 83: 1287-1293.
- Campeau, L. (1984):**
The relation of risk factor to the development of atherosclerosis in saphenous vein bypass grafts.
N. Engl. J. Med., 311:1329.
- Castelli, W.P. (1986):**
The TG issue: a view from framingham.
Am. Heart J; 112: 432-7.
- Castellino, F.J. (1981):**
Recent advance in the chemistry of the fibrinolytic system.
Chem. Rev., 81:431.
- Cazzolato, G.; Prakasch, G.; Green, S. and Kostner, G.M. (1983):**
The determination of Lp (a) by rate and end point nephelometry.
Clinica Chimica Acta, 135: 203.

- Charles, S.; Michel, M.; Eva, W.; Brain, M.; Gilfix, Jacques, L. and Lucien, C. (1993):**
Relation of CAD in women < 60 years of age to the combined elevation of serum Lp (a) and TC/HDL ratio.
Am. J. cardiol. 72: 1215-1219.
- Corsetti, J.P.; Sterry, J.A.; Sparks, J.D.; Sparks, C.E. and Weintraub, M. (1991):**
Effect of weight loss on serum Lp (a) concentrations in an obese population.
Clinical chemistry, 37: 1191.
- Craig, W.Y.; Poulin, S.E.; Forster, N.R. and Ledue, T.B. (1992):**
Effect of sample storage on the assay of Lp (a) by Commercially available Radial immunodiffusion and ELISA kits.
Clin. Chem., 38: 550.
- Crook, D.; Sidhu, M.; Seed, M. and Stevenson, J.C. (1992):**
Lp (a) levels are reduced by danazol, an anabolic steroid.
Atherosclerosis, 92: 41.
- Dahlen, G.; Berg, K.; Gillans, T. and Ericson, C. (1975):**
Lp (a)/pre-B₁- lipoprotein in swedish middle-aged males and in patients with CAD.
Clin. Genet., 7: 334.
- Dahlen, G.; Frick, M.H.; Berg, K.; Valle, M. and Witjasato, M. (1975 [11]):**
Further studies of Lp (a) /pre-B₁- lipoprotein in patients with CAD.
Clin. Genet., 8:183.
- David, J.; Richard, A.L.; Robert, S.M.; John, E.W.; Helen, H. and Eric, B. (1993):**
Relation of plasma Lp (a) to infarct artery patency in survivors of myocardial infarction.
Circulation. 88: 935-940.
- Deknijff, P.; Kaptein, A.; Boomsma, D. and Havekes, L. (1991):**
Apo E polymorphism affects plasma levels of Lp (a).
Atherosclerosis, 90: 169.

- Depoli, P.; Bacon, B.T.; Kendra, F.S.; Cederholm, M.T. and Wattz, D.A. (1989):**
Thrombospondin interaction with plasminogen. Evidence for binding to a specific region of the kringle structure of plasminogen.
Blood, 73: 976.
- Dieplinger, H.; Lackner, C.; Kronenberg, F.S.; Holzer, C. and Lhotta, K. (1993):**
Elevated plasma concentrations of Lp (a) in patients with end stage renal disease are not related to the size polymorphism of apo (a).
J. Clin. Invest., 91: 397.
- Dong, L.M.; Yamamura, T. and Yamamota, A. (1990):**
Enhanced binding activity of apo E mutant E₅ to LDL receptors.
Biochem. Biophys. Res. Common., 168: 409.
- Durington, P.N.; Hunt, I and Ishola, M. (1986):**
Serum Apo-A-1 and B and lipoproteins in middle-aged men with and without previous MI.
Br. Heart. J. 56: 206.
- Durington, P.N.; Ishola, M. and Hunt, L. (1988):**
Apo-A, A-1 and B and parental history in men with early onset IHD.
Lancet, 14: 1070, 1988.
- Eaton, D.L.; Fless, G.M.; Kohr, W.J.; Mclean, J.W.; Miller, C.G.; Lawn, R.M. and Scanu, A.M. (1987):**
Partial amino acid sequence of apo (a) shows that it is homologous to plasminogen.
Proc. Natl. Acad., Sci.USA, 84: 3224.
- Edelberg, J.M.; Gonzalez, G. and Pizzo, S. (1989):**
Lp (a) inhibits streptokinase-mediated activation of human plasminogen.
Biochemistry. 28: 2370 - 2374.

- Ehnholm, C.; Garoff, H.; Renkonau, O. and Simons, K. (1972):**
Protein and Carbohydrate composition of Lp (a) lipoprotein from human plasma. *Biochemistry*, 11: 3229.
- Ehnholm, C.; Garoff, H. Simons, K. and Aro, H. (1971):**
Purification and quantitation of human plasma lipoprotein carrying the Lp (a) antigen.
Biochem. Biophys. Acta., 236:431.
- Eisenberg, S. (1984):**
High density lipoprotein metabolism.
J. lipid Res., 25: 1017.
- Etingin, O.R.; Hajjar, D.P.; Hajjar, K.A.; Harpel, P.C. and Nacman, R.L. (1991):**
Lp (a) regulate plasminogen activator inhibitor-1 experssion in endothelial cells. A potential mechanism in thrombogenesis.
J. Biol. Chem., 266: 2459.
- Finley, R.R. (1978):**
Methods of Estimation of HDL-C.
Clin. Chem. 24: 931.
- Flegg, H.M. (1973):**
Enzymatic colorimetric methods for determination of serum total cholesterol.
Ann. Clin. Biochme. 10: 79.
- Fless, G.M. and Scanu, A.M. (1986):**
Lp (a): Biochemistry and biology. In: *Biochemistry and Biology of plasma lipoproteins*, 2nd edition.
New York, Marcel Dekker, Inc., P. 73.
- Fless, G.M.; ZumMallen, M.E. and Scanu, A.M. (1985):**
Isolation of apo (a) from Lp (a).
Journal of lipid Research, 26: 1224.
- Fless, G.M. and Scanu, A.M. (1987):**
Immunological cross-reactivity of human lipoprotein (a) with plasminogen.
Arteriosclerosis, 7: 505 a.

- Fless, G.M.; Synder, M.L. and Scanu, A.M. (1989):**
Enzyme-linked immunoassay for Lp (a).
Journal of lipid Research, 30: 651.
- Frank, S.L.; Klisak, I.; Sparkes, R.S.; Mohandas, T.; Lawn, R.M. and Lusic, A.J. (1988):**
The apo (a) gene resides on human chromosome 6 in close proximity to the homologous gene for plasminogen.
Hum. Genet., 79: 352.
- Friedwald, W.T. (1972):**
Estimation of LDL-C in plasma, without use of the preparative ultracentrifuge.
Clin. Chem., 18: 499.
- Fuster, V.; Chesebro, B. (1986):**
Mechanism of unstable angina.
N. Engl. J. Med. 315 (16): 1023-5.
- Garoff, H., Simons, K.; Ehnholm, C. and Berg, K. (1970):**
Demonstration by disc electrophoresis of the lipoprotein carrying the Lp (a) antigen in human sera.
Acta Path. Microbiol. Scand., 78: 253.
- Gaubatz, J.W.; Charl, M.V.; Nava, M.L.; Guyton, J.R. and Morrisett, J.D. (1987):**
Isolation and characterization of the two major apoproteins in human Lp (a).
J. lipid Research, 28: 69.
- Gaubatz, J.W.; Cushing, G.L. and Morrisett, J.D. (1986):**
quantification, isolation and characterization of human Lp (a)
Methods Enzymol., 29: 167.
- Gaubatz, J.W.; Ghanem, K.I., Guevara, Jr.J.; Nava, M.L.; Patsch, W. and Morrisett, J.D. (1990):**
Polymorphic forms of human apo (a): Inheritance and relationship of their molecular weights to plasma levels of Lp (a).
J. lipid Research, 31: 603.

- Gavish, D.; Azrolan, N. and Breslow, J. (1989):**
 Plasma Lp (a) concentration is inversely correlated with the ratio of kringle IV/kringle V encoding domains in the apo (a) gene.
 J. Clin. Invest., 84: 2021.
- Genest, J.; Jenner, J.L.; McNamara, J.R.; Ordovas, J.M.; Silberman, S.R.; Wilson, P.W.F. and Schaefer, E.J. (1991):**
 Familial lipoprotein disorders in patients with premature CAD circulation, 85: 2025.
- Genest, J.; Martin-Munty, S.S.; McNamara, J.R.; Ordovas, J.M. and Schaefer, E.J. (1992):**
 Familial lipoprotein disorders in patient with premature CAD circulation, 85:2025.
- Genest, J.; McNamara, J.R.; Ordovas, J.M.; Jenner, J.L.; Wilson, W.F.; Salem, D.N. and Schaefer, E.J. (1992 [11]):**
 Lp cholesterol, apo-A₁ and B and Lp (a) abnormalities in men with premature CAD.
 J. Am. Coll. Cardiol., 19: 792.
- Ghilain, J.M.; Parfomy A.; Kozyreff, V. and Heller, F. (1988):**
 Lp (a) cholesterol and CAD.
 Lancet, 22: 963.
- Gillery, P.; Arthuis, P.; Cuperlier, C. and Circaud, R. (1993):**
 Rate nephelometric assay of serum Lp (a).
 Clin. Chem., 39:503.
- Ginsberg, H.N. and Goldberg, J. (1986):**
 Apo B metabolism in subjects with deficiency of apo-C-III and A-I.
 J. Clin. Invest., 78: 1287.
- Glueck, C.J.; Suchindran, C.M., Chambless, L.E., Stewart, P. and Tyroler, H.A. (1986):**
 Progenys lipid and lipoprotein levels by parental mortality.
 The lipid Research clinics program prevalence study.
 Circulation. 73: 151.

- Gries, A. and Kostner, G. (1990):**
Lp (a) an atherogenic risk factor in human serum.
Z. Med. Lab. Diagn; 31: 355-60.
- Gubbini, B., Galli, M., Campini, R. (1991):**
Effects of mental stress on myocardial perfusion in patients with IHD.
Circulation, 83: 100-107.
- Gurakar, A.; Hoeg, M.; Kostner, G.; papadopoulos, N.M. and Brewer, H.B. (1985):**
Levels of Lp (a) decline with neomycin and niacin treatment.
Atherosclerosis, 57: 293.
- Guyton, J.R.; Dahlen, G.; Patsch, W.; Kautz, J.A. and Gotto, A.M. (1985):**
Relationship of plasma Lp (a) levels to race and to apolipoprotein B.
Arteriosclerosis, 5: 265.
- Hajjar, K.A.; Gavish, D.; Breslow, J.L. and Nachman, R.L. (1989):**
Lp (a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis.
Nature, 339:303.
- Hamstern, A.; Faire, U. and Walldius, G. (1987):**
PAI in plasma : risk factor for recurrent MI.
Lancet; 1: 3-9.
- Harvie, N.R. and Schultz, J.S. (1973):**
Studies on the heterogeneity of human serum lipoproteins and on the occurrence of double lipoprotein variants.
Biochem. Genet., 9: 235.
- Hasstedt, S.J.; Wilson, D.E.; Edwards, C.O.; Cannon, W.N.; Carmelli, D. and Williams, R.R. (1983):**
The genetics of quantitative plasma Lp (a): Analysis of a large pedigree.
Ann. J. Med. Genet., 16: 179.

- Havel, R.J.; Goldstein, J.L. and Brown, M.S. (1980):**
Lipoprotein and lipid transport. In: Metabolic control and disease, 3rd edition, Bondy, P.K. and Rosenberg, L.K (eds). W.B. saunders Co., philadelphia, P. 393.
- Hearn, J.A.; Demaio, S.J.; Roubin, G.S. and Sgoutas, D. (1991):**
Predictive value of Lp (a) and other serum lipoproteins in the angiographic diagnosis of CAD.
Am. J. cardiol. 66: 1176-1180.
- Hegele, R.A.; Freeman, M.R.; Langer, A.; Cannely, P.W. and Armstrong, P.W. (1992):**
Acute reduction of Lp (a) by t-PA circulation, 85: 2034.
- Heinrich, J.; Sandkamp, M.; Kokt, R.; Schuttz, H. and Assmann, G. (1991):**
Relationship of Lp (a) to variables of coagulation and fibrinolysis in a healthy population.
Clinical chemistry, 37: 1950.
- Henriksson, P.; Angelin, B. and Berglund, L. (1992):**
Hormonal regulation of serum Lp (a) levels. opposite effects after estrogen treatment and orchidectomy in males with prostatic carcinoma.
J. Clin-invest., 13: 171.
- Herbert, P.N.; Asmann, G.; Gotto, A.M. and Fredrickson, D.S. (1982):**
Familial lipoprotein deficiency in: The metabolic basis of inherited disease., 2nd edition. goldstein, J.L. and Brown, M.S. (eds). McGraw Hill Inc., New York, P. 589.
- Herrmann, V.W.; Hanf, S. Lindhofer, H. and Oswald, B. (1988):**
Zurdiagnostischen wertigkeit von lipiden and Apo fur die Beschreibung des atherogenen Risikos.
Z. Gesamte Inn. Med., 43: 86.
- Hoff, H.F.; Beck, G.J. and Skibiniski, C.I. (1988):**
Serum Lp (a) levels as a predictor of vein graft stenosis after coronary artery by pass surgery in patietns.
Circulation, 77: 1238.

- Hofmann, S.L.; Eaton, D.L.; Brown, M.S.; McConathy, W.J.; Goldstein, J.L and Hammer, R.E. (1990):**
Overexpression of human LDL receptors lead to accelerated catabolism of Lp (a) in transgenic mice.
J. Clin. Invest., 85: 1542.
- Holmes, D.R.; Elveback, R.L.; Frye, R.L. and Ellefson, R.D. (1981):**
Association of risk factor variables and CAD documented with angiograph.
Circulation., 63: 293-299.
- Huang, C.M.; Kraft, H.G. and Gregg, R.E. (1991):**
Modified immunoblotting technique for phenotyping Lp (a).
Clin. Chem., 37: 576.
- Hurst, J.W. (1990):**
The heart
Text book of cardiovascular disease 7th edition.
- Iselius, L.; Dahlen, G.; Defaire, U. and Lundman, T. (1981):**
Complex segregation analysis of the Lp (a)/ pre-B₁ lipoprotein trait.
Clin. Genet., 20: 147.
- Jacques, G.J.; Jennifer, L.J.; Judith, R.M.C.; Jose, M.O.; Stern, R.S.; Peter, W.F. and Ernst, J.S. (1991):**
Prevalence of Lp (a) Excess in CAD.
The American Journal of Cardiology May. 15, Vol. 17.
No. 13: 1039-1045.
- JAMES, B.W.; LLOYD, H.S and CLAUDE, B. (1992):**
Nutritional Assessment.
CECIL T.B of Medicine, volume 2, 19th ed., P 1152.
by W.B SAUDERS company.
- Jansson, J.H.; Olofsson, B.O.; Nilsson, T.K. (1993):**
Predictive value of t-PA mass concentration on long term Mortality in patients with CAD.
Circulation, 88 [part 1]: 2030-2034.

- Jauhiainen, M.; Koskinen, P.; Ehnholm, C. and Frick, M. (1991):**
Lp (a) and CAD risk: a nested case control study of the helsinki heart study participants.
Atherosclerosis; 89: 59-67.
- Jennifer, L.J.; Jose, M.O.; Stefania, L.F.; Mary, M.S.; Peter, W.F.W., William, P.C. and Ernst, J.S. (1993):**
Effect of Age, Sex and menopausal status on plasma Lp (a) levels.
Circulation; 87: 1135-1141.
- Jurgens, G.; Hermann, A.; Aktuna, D. and Petek, W. (1992):**
Dissociation-Enhanced Lanthanide Fluorescence immunoassay of Lp(a) in Serum.
Clin. Chem., 38: 853.
- Kannel, W.B. (1989):**
Detection and management of patients with silent myocardial ischemia.
Am. Heart, J. 117: 221-226.
- Kaplan, L.A. and Pesce, A.J. (1989):**
Disorders of lipid metabolism. In: Clinical chemistry, theory, Analysis and Correlation, 2nd edition.
CV Mosby company, st. louis, Missouri, P. 468.
- Karadi, I., Kostner, G.M., Gries, A., Nimpf, J., Romics, L. and Malle, E. (1988):**
Lp (a) and plasminogen are immunochemically related.
Biochim. Biophys. Acta., 960: 91.
- Kluft, C.; Jie, A.F.H.; Los, P.; Wit, E. and Havekes, L. (1989):**
Functional analogy between Lp (a) and plasminogen in the binding to the kringle 4 binding protein, tetranectin.
Biochem. Biophys. Res. Commun., 161: 427.
- Knott, T.J.; Powell, L.M., Rall, Jr.S.C, Taylor, W.H., Johnson, D. Mahley, R.W., and Scott, J. (1986):**
Complete protein sequence and identification of structural domains of human apo B.
Nature, 323: 734.

Kostner, G.M. (1986):

Lp (a): Structural and Functional Aspects. In: Atherosclerosis VII, 1st edition. Fidge, N.H. and Nestel, P.J. (eds) Elsevier Science publishers, p. 267.

Kostner, G.M.; Avogaro, P., Cazzolato, G., Marth, E., Bittolobon, G. and Qunici, G.B. (1981):

Lp (a) and the risk for myocardial infarction.
Atherosclerosis, 38: 51.

Kostner, G.M.; Gries, A.; Pometta, M.; Molinari, E.; Pichier, P. and Aicher, H. (1990):

Immunochemical determination of Lp (a): comparison of laurell electrophoresis and ElisA.
Clinical Chimica Acta, 188: 187.

Kottke, B.A. (1986):

Lipid markers for atherosclerosis.
Am. J. Cardiol., 57; 57: 11c.

Kraft, H.G.; Manzel, H.J.; Hoppichler, F.; Vogel, W. and Utermann, G. (1989):

Changes of genetic apo phenotypes caused by liver transplantation. Implications for apolipoprotein synthesis.
J. Clin. Invest., 83: 137.

Kraft, H.C.; Sandholzer, C.; Menzel, H.J. and Utermann, G. (1992):

Apo (a) alleles determine Lp (a) particle density and concentration in plasma.
Arteriosclerosis. Thromb, 12: 302.

Krempler, F.; Kostner, G.M.; Bozano, K. and Sandhofer, F. (1978):

Studies on the metabolism of the Lp (a) in man.
Atherosclerosis, 30: 57.

Krempler, F.; Kostner, G.M.; Bozano, K. and Sandhofer, F. (1979):

Lp (a) is not a metabolic product of other lipoproteins containing apo B.
Biochim. Biophys. Acta., 575: 63.

- Krempler, F.; Kostner, G.M.; Bolzano, K. and Sandhofer, F. (1980):**
Turnover of Lp (a) in man.
J. Clin. Invest., 65: 1483.
- Krempler, F.; Kostner, G.M.; Roscher, A.; Haslauer, F.; Bolzano, K. and Sandhofer, F. (1983):**
Studies on the role of specific cell surface receptors in the removal of Lp (a) in man.
J. Clin. Invest., 71: 1431.
- Kukita, H.; Hiwada, K. and Kokuba, T. (1984):**
Serum apo-A-1, A-II and B levels and their discriminative values in relations of patients with CAD.
Atherosclerosis. 51: 261.
- Krutz, N.R. (1983):**
Introduction to social statistics, 3rd edition.
McGraw-Hill Book Company, New York, P. 163.
- Labour, C.D.; DeBacquer, G.; Backer, J.; Unckel and Muylde mans. (1992):**
Plasma Lp (a) values and severity of CAD in a large population of patients undergoing coronary angiography.
Clin. Chem. 38: 2261-2266.
- Laurell, C.B. (1966):**
Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies.
Anal. Biochem. 15: 45.
- Lawn, R.M. (1992):**
Lp (a) in heart disease.
Sci. Am., 266-54.
- Lawrence, A.K.; Amadeo, J.P. (1989):**
The C.V Mosby company-philadelphia.
Clin. Chemistry 2nd Edition (17): 417.
- Lefewe, M. and Roheium, P.S. (1984):**
Metabolism and apo A-II.
J. Lipid Research, 25: 1603.

Levy, R. and Feinleib, M. (1984):

Risk factors for CAD and their management: Heart disease
Vol. 2A T.B of cardiovascular medicine. 3rd ed. by
Braunwalled saunder company.
Philadelphia. London, P 1205.

Lindahl, G.; Gersdorf, E.; Menzel, H.J.; Duba, C. and Utermann, G. (1989):

The gene for the Lp (a) specific glycoprotein is closely linked
to the gene for plasminogen on chromosome 6.
Hum. Genet., 81: 149.

Livshits, G.; Weisbort, J.; Meshulam, N. and Brunner, D. (1989):

Multivariate analysis of the twenty-year follow up of Donolo-
Telaiv. prospective CAD study and the usefulness of HDL-C
percentage.
Am. J. cardiol. 63: 676-681.

Loscalzo, J.; Fless, G.M. and Scanu, A.M. (1988):

Lp (a) inhibits fibrin-dependent enhancement of tissue
plasminogen activator activity.
Blood, 72: 370 a.

Lou, S.C.; Patel, C.; Ching, S.F. and Gordon, J. (1993):

One-step competitive immunochromatographic assay for
semiquantitative determination of Lp (a) in plasma.
Clin. Chem., 39: 619.

Mahly, R.W. and Innerarity, T.L. (1983):

Lipoprotein receptors and cholesterol homeostasis.
Biochim. Biophys. Acta, 737: 197.

Mancini, G.; Carbonara, A. and Heremans, J. (1965):

immunochemical quantitation of antigens by single radial
immunodiffusion.
Immunochemistry, 2:235.

Mark, R. and Goldstein (1993):

Coronary heart disease in the elderly.
Circulation volume 87 no 5: 1773.

Marshall, W.J. (1990):

lipids and lipoproteins. In: illustrated text book of clinical chemistry. 1st edition. Good fellow and Moehrle (eds). J.B lippincott company, philadelphia, p 219.

Marth, E.; Gazzolato, G.; Bittolo, B.G. and Avogaro, P. (1982):

Serum concentrations of Lp (a) and other lipoprotein parameters in heavy alcohol consumers.
An. Nutr. Metabol., 26: 56.

Marz, W.; Trommlitz, M.; Scharrer, L. and Gross, W. (1991):

Apo (a) concentrations are not related to the risk of venous thrombosis.
Blood coagulation fibrinolysis, 2: 595.

Maseri, A. and Chierchia, S. (1982):

Coronary artery spasm: Demonstration, definition, diagnosis and consequences.
Prog. cardiovasc. Dis., 25: 169.

Matti, N.; Kimo, K.; Kari, N. and Tero, S. (1990):

HDL-C and TG as markers of angiographically assessed CAD.
Br. Heart. J., 63: 78-81.

McLean, J.W.; Tomlinson, J.E.; Kuang, W.J.; Eaton, D.L.; Chen, E.Y.; Fless, G.M.; Scanu, A.M. and Lawn, R.M. (1987):

cDNA sequence of human apo (a) is homologous to plasminogen.
Nature, 330:132.

Miles, L.A.; Fless, G.M.; Levin, E.G.; Scanu, A.M. and Plow, E.F. (1989):

Apotential basis for the thrombotic risks associated with Lp (a).
Nature, 339:301.

Miller, N. (1987):

HDL. A major risk factor for coronary atherosclerosis.
Clin. Endocrinol. Metabol., 1: 603.

- Miller, M.; Bacharik, P.S. and Cloey, T.A. (1992):**
Normal variation of plasma lipoproteins: postural effects on plasma concentration of lipids, lipoproteins and apolipoproteins.
Clin. Chem., 38: 569.
- Miller, M.; Mead, L.A.; Kwiterovich, P.O. and Pearson, T.A. (1990):**
Dislipidemias with desirable plasma total cholesterol levels and angiographically demonstrated CAD.
Am. J. Cardiol. 65: 1-5.
- Moghazy, th. and El-Banawy, S. (1994):**
Lp (a): An independent risk factor for CAD.
ARAB Journal of Lab. Med. volume, 20, No. 3.
- Morrisett, J.D., Nava, M.L.; Ganem, K.K.; Jones, P.H. (1992):**
Metabolic relationship between plasma Lp (a) and TG.
In stein O., Eisenberg S., stein Y. (eds):
Atherosclerosis 1X Telaviv, R & L. pp. 123-126.
- Murray, A.; Miyahara, T.; Fujimoto, N.; Matsuda, M. and Kameyama, M. (1986):**
Lp (a) as a risk factor for CAD and cerebral infarction.
Atherosclerosis, 59: 199.
- Naseem, A.; Jaffrani, Seymour, E. and John, S. (1993):**
Therapeutic approach to unstable angina:
Am. Heart. Journal volume 126, no 5: 1239-1241.
- Nikkila, M.; Koivula, T.; Niemela, K. Sisto, T. (1990);**
HDL-C and TG as markers of angiographically associated CAD.
Br. Heart. J., 63: 78-81.
- Noma, A.; Yokosuka, T. and Kitamura, K. (1983):**
Plasma lipids and apolipoproteins as discriminators for the prescence and severity of angiographically CAD.
Atherosclerosis. 49 (1): 1.
- Oliver, M.F. (1987):**
Dietary fat and CAD
Br. Heart. J., 58: 423-428.

- Olofsson, S.; McConathy, W. and Aaupovic, P. (1977):**
Isolation and partial characterization of an acidic apoprotein from Human HDL.
Circulation, 56: 111-56.
- Osborne, J.C. and Brewer, H.B. (1977):**
The plasma lipoproteins (Review).
Adv. prot. Chem., 31: 253.
- Packard, C.J.; Third, J.L.H.C., Shepherd, J., Lorimer, A.R., Morgan, H.G. and Lawrie, T.D.V. (1976):**
LDL metabolism in a family of familial hypercholesterolemic patients.
Metab. Clin. Exp., 25: 995.
- Panel Report. (1988):**
Report of the National Cholesterol Education Program Expert panel on detection, Evaluation, and treatment of high blood cholesterol in adults.
Arch. intern. Med., 148: 36-69.
- Panteghini, M. and Pagani, F. (1991):**
Serum concentrations of Lp (a) during pregnancy and postpartum.
Clinical chemistry, 37: 2009.
- Pometta, D.; Suenram, A.; Sheybani, E.; Brab, B. and James, R. (1986):**
HDL-C levels in patients with MI and their families atherosclerosis. 59:21.
- Rath, M.; Niendorf, A and Reblin, T. (1989):**
Detection and quantification of Lp (a) in arterial wall of 107 coronary by pass patients.
Atherosclerosis; 9. 579-92.
- Rees, A. (1991):**
Lp (a): A possible link between lipoprotein metabolism and thrombosis.
Br. Heart J., 65: 2.

- Renninger, W., Wendtt, G.G. and Weighand, H. (1965):**
Beitrage zurprolelemalik des Lp-system.
Human genetic, 1: 658.
- Rhoads, G.; Dahlen, G.; Berg, K.; Morton, N. and Dannenberg, A. (1986):**
Lp (a) as a risk factor for MI.
JAMA; 256: 2540-4.
- Rider, A.K.; Levy, R.I. and Frdrickson, D.S. (1970):**
Sinking pre-beta lipoprotein and the Lp antigen.
Circulation, 42 :10.
- Rifai, N. (1986):**
Lipoproteins and apolipoproteins.
Arch. pathol. Lab. Med., 110: 694.
- Romics, L., Karadi, I., Gaszar, A. and Kostner, G.M. (1990):**
Physiological and clinical importance of Lp (a).
Tokai, J. Exp. Clin. Med., 15: 149.
- Rouy, D.; Graithe, P.; Nigon, F., chapman, J. and Angles cono, E. (1991):**
Lp (a) impairs generation of plasmin by fibrin-bound tissue-type plasminogen activator,
Arteriosclero. thromb., 11-629.
- Ruppert, M.; Diehl, J.; Kolloch, R.; Over Lack, A.; Kraft, K.; Gobel, B.; Hittel, N. and Stumpe, K.O. (1991):**
Short-term dietary sodium restriction increases serum lipids and insulin in salt-sensitive and salt resistant normotensive adults.
Klin. Wochenschr., 69: 51.
- Sandholzer, C.; Boerwinkle, E.; Saha, N.; Tong, M.C. and Utermann, G. (1992):**
Apolipoprotein (a) phenotypes. Lp (a) cocentration and plasma lipid levels in relation to CAD in a chinese population: Evidence for the role of the apo (a) gene in CAD.
J. Clin. Invest., 89: 1040.

- Sandholzer, C.; Hallman, D.M.; Saha, N.; Sigurdsson, G.; Lackner, C.; Cazzar, A.; Boerwinkle, E. and Utermann, G. (1991):**
Effects of the apo (a) size polymorphism on the Lp (a) concentrations in 7 ethnic groups.
Hum. Genet., 86: 607.
- Sandkamp, M.; Funke, H.; Schulle, H.; Kohler, E. and Assman, G. (1990):**
Lp (a) is an independent risk factor for MI at young age. Clin. Chem., 36: 20.
- Sathanur, R.S.; Costa, H.D.; Rafael, A.J.; Larry, S.W. and Gerald, S.B. (1991):**
Racial (Black-white) difference in serum Lp (a) distribution and its relation to parental MI in children.
Circulation. 84. 1:160-167.
- Scanu, A.M. (1991):**
Lp (a) and atherosclerosis.
Ann. intern. Med., 115: 209.
- Scanu, A.M. (1992):**
Lp (a). A genetic risk factor for premature CAD.
JAMA, 267: 3329.
- Scanu, A.M. and Landsberger, F.R. (1980):**
Lipoprotein structure.
Ann. N.Y. Acad. Sci., 348:1.
- Scanu, A.M.; Pfaffinger, D.; Fless, G.M.; Makino, K.; Eisenbart, J. and Himman, J. (1992):**
Attenuation of immunologic reactivity of Lp (a) by thiols and cysteine-containing compounds. Structural implications.
Arterioscler thromb., 12: 424.
- Schaefer, E.J. and Levy (1985):**
Lipoprotein apoprotein metabolism.
J. Lipid Res., 19: 667.

Schriewer, H.; Assmann, G. and Sandkamp, M. (1984):

The relationship of Lp (a) to risk factors of CAD: Initial results of the prospective epidemiological study on company employees in westfalia.

J. Clin. Chem. Clin. Biochem., 22:591.

Shaper, A.G. and Pocock, S.J. (1987):

Risk factors for IHD in British men.

Br. Heart. J., 57: 11-16.

sheperd, J. and Pachard, C.J. (1987):

Lipid transport through the plasma: The metabolic basis of hyperlipidemia.

J. Clin. Endocrinol. Metabol., 1: 495.

Shepherd, J. and Packard, C.J. (1988):

Regression of coronary atherosclerosis: Is it possible?

Br. Heart. J., 59: 149-150.

Silva, J.M.; Maldonado, J.; Rocha, I.; Costa, A.; Morais, J.; Morais, M.E.; Providencia, L.A. and Silva, P.S. (1992):

Relations between the levels of Lp (a) and results of coronarography in patients with IHD. preliminary results.

Rev. Port. Cardiol., 11:139.

Simon, D.I., Fless, G.M., Scanu, A.M. and Loscalzo, J. (1991):

Tissue-type plasminogen activator binds to and is inhibited by surface-bound lipoprotein (a) and LDL.

Biochemistry, 30: 6671.

Simons, L.A.; Reichl, D.; Myant, N.B. and Mancini, M. (1975):

The metabolism of the apoprotein of plasma LDL in familial hyperbetalipoproteinemia.

Atherosclerosis, 21: 283.

Sing, C.F.;Schultz, J.S. and Shreffler D.C. (1974):

The genetics of the Lp antigen. II. A family study and proposed models of genetic control.

Ann. Hum. Genet., 38:47.

Smith, E. and Cochran, S. (1990):

Factors influencing the accumulation in fibrous plaques of lipid derived from LDL, II: preferential immobilization of Lp(a).

Atherosclerosis; 84: 173-81.

Snyder, M.L.; Polacek, D.; Scanu, A.M. and Fless, G.M. (1992):

Comparative binding and degradation of Lp (a) and LDL by human monocyte-derived macrophages.

J. Biol. Chem., 267: 339.

Soria, J.; Soria, C. and Samama, M. (1978):

Plasminogen assay using a chromogenic synthetic substrate: Results from clinical work and from studies of thrombolysis.

In: Davidson et al. (eds). progress in chemical fibrinolysis and thrombolysis. volume 3.

Raven, New York, 337-346.

Srinivasan, S.R.; Dahlen, G.H.; Jarpa, R.A.; Webber, L.S. and Berenson, G.S. (1991):

Racial (Black-white) differences in serum Lp (a) distribution and its relation to parental MI in children. Circulation, 84: 160.

Steinberg, D. (1989):

The cholesterol controversy is over why did it take so long.

Circulation, 80: 1070-1078.

Steiner, G.; Schwartz, L.; Shumack, S. and Poapst, M.; (1987):

The association of increased levels of intermediate density lipoproteins with smoking and with CAD.

Circulation, 75: 124-130.

Tatami, R.; Mabuchi, H. and Ueda, K. (1981):

IDL and cholesterol rich VLDL in angiographically determined CAD. circulation, 64: 1174.

Teitz, N.W. (1987):

Lipids, Lipoproteins and apolipoproteins, in: fundamentals of clinical chemistry. 3rd edition.

W.B. Saunders, Philadelphia, p 448.

- Tomlinson, J.E; Mclean, J.W and Lawn, R.M. (1989):**
Rhesus monkey apo (a): Sequence, evolution and site of synthesis.
J. Biol.Chem. 264:5957.
- Trinder, P. (1969):**
Enzymatic estimation of glucose level in plasma.
Ann. Clin. Biochem., 6: 24.
- Utermann, G. (1989):**
The mysteries of lipoprotein (a).
Science, 246: 904.
- Utermann, G.; Duba, C.; Menzel, H.J. and Seitz, C. (1988 [11]):**
Genetics of the quantitative Lp (a) trait. II. Inheritance of Lp(a) glycoprotein phenotypes.
Hum. Genet., 78: 47.
- Utermann, G.; Kraft, H.G.; Menzel, H.J.; Hopferwiser, I. and Sotz, C. (1988):**
Genetics of the quantitative Lp (a) trait. I. Relation of Lp (a) glycoprotein phenotypes to Lp (a) concentrations in plasma.
Hum. Genet., 78: 41.
- Utermann, G.; Menzel, H.J.; Kraft, H.G.; Duba, C.; Kemmle, H.G. and Seitz, C. (1987):**
Lp (a) glycoprotein phenotypes: Inheritance and relation to Lp (a) concentrations in plasma.
J. Clin. Invest. 80: 458.
- Utermann, G. and Weber, W. (1983):**
Protein composition of Lp (a) from human plasma.
Febs. Letters, 154: 357.
- Valimäki, M.; Laitinen, K.; Ylikahri, R.; Ehnholm, C.; Bard, J.M.; Fruchart, J.C. and Taskinen, M.R. (1991):**
The effect of moderate alcohol intake on serum apo-A-I containing lipoproteins and Lp (a).
Metabolism, 40: 1168.

- Vella, J.C. and Jover, E. (1993):**
Relation of Lp (a) in 11-19 year-old adolescents to parental cardiovascular disease.
Clin. Chem., 39: 477.
- Verbruggen, R. (1975):**
Quantitative immunoelectrophoretic methods: A literature survey.
Clin. Chem., 21:5.
- Vessby, G.; Kostner, G.M.; Lithel, H. and Thomis, J. (1982):**
Diverging effects of cholestyramine on apo B and Lp (a).
Atherosclerosis, 44: 61.
- Voller, A.; Bidwell, D.E. and Bartlett, A. (1979):**
ELISA: A guide with abstracts of microplate applications.
Dynatech Laboratories, Alexandria, Va.
- Von Hodenberg, E.; Kreuzer, J.; Hautmann, M.; Nordt, T.; Kubler, W. and Bode, C. (1991):**
Effects of Lp (a) on success rate of thrombolytic therapy in acute myocardial infarction.
Am. J. Cardiol., 67: 1349.
- Vu-Dac, N.; Chekkor, A.; Parra, H. and Fruchart, J.C. (1985):**
Latex immunoassay of human serum Lp (a).
J. Lipid Res., 26: 267.
- Wade, D.P.; Knight, B.L.; Hrders-spengel, K. and Soutar, A.K. (1991):**
Detection and quantitation of apo (a) mRNA in human liver and its relationship with plasma Lp (a) concentration.
Atherosclerosis, 91: 63.
- Wahefeld, A.W. (1974):** In Methods of Enzymatic Analysis. Vol. 5, Hubergmeyer. Ed. Academic press, New York: pp. 1831-1835.
- Walton, K.W.; Hitchens, J.; Magnani, H.N. and Khan, M. (1974):**
A study of methods of identification and estimation of Lp (a) lipoprotein and of its significance in health, hyperlipidemia and atherosclerosis.
Atherosclerosis, 20: 323.

Wange, X.L.; Wilcken, D.E. and Dudman, N.P. (1992):

Early expression of the apo (a) gene: Relationships between infants and their parents serum apo (a) levels.

Pediatrics, 89: 401.

Watts, G.F.; Kedrney, E.M.; Taub, N.A.; Salvin, B.M. (1993):

Lp (a) as an independent risk factor for MI in patient with common hypercholesterolaemia.

J. Clinical pathology, 46: 267-270.

Wong, W.; Eaton, D.; Berloui, A.; Fendly, B. and Hass, P. (1990):

A monoclonal antibody based Eliza of Lp (a).

Clin. Chem., 36 (2): 192-7.

Wynder, E.L.; Harris, R.E. and Haley, N.J. (1989):

Population screening for plasma cholesterol; community based results from connecticut.

Am. Heart. J., 117:649-656.